Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet

被引：0

作者：

Klimek L. ^{[1
]}

Brehler R. ^{[2
]}

Casper I. ^{[1
]}

Klimek F. ^{[1
]}

Hagemann J. ^{[3
]}

Cuevas M. ^{[4
]}

Bergmann K.-C. ^{[5
,6
]}

机构：

[1] Center for Rhinology and Allergology, Wiesbaden

[2] Clinic for Skin Diseases, Münster University Hospital, Muenster

[3] Department of Otorhinolaryngology, Mainz University Medical Center, Mainz

[4] Clinic and Polyclinic for Otorhinolaryngology, Carl Gustav Carus University Hospital, TU Dresden, Dresden

[5] Institute for Allergy Research, Charité—Universitätsmedizin Berlin, Berlin

[6] Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin

来源：

Allergo Journal International | 2023年 / 32卷 / 1期

关键词：

Allergen immunotherapy; Allergic asthma; Allergic rhinitis; House mites; Mite tablet;

D O I：

10.1007/s40629-022-00241-6

中图分类号：

学科分类号：

摘要：

Background: A perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life of patients and is associated with a high socioeconomic burden. The most common symptoms of allergic rhinitis include a runny nose and nasal congestion, sneezing, itching of nose, mouth and/or throat, and/or ocular symptoms. Affected patients often develop allergic bronchial asthma. Therapy options for allergic rhinitis include allergen avoidance, symptomatic treatment, and allergen immunotherapy. Allergen immunotherapy is the only disease-modifying treatment that can permanently alleviate the symptoms of allergic rhinitis. In July 2021, a new sublingual mite tablet was approved in Germany. Methods: This review summarizes clinical studies on the 300 IR (index of reactivity) mite tablet in adolescents and adults with house dust mite-associated allergic rhinitis and presents the results. Results: In the phase II and phase III studies considered here, different dosages of the mite tablet were investigated. The 300 IR mite tablet showed the best benefit–risk profile and has been approved in Europe, Japan, South Korea, Australia, and New Zealand for the treatment of house dust mite-associated allergic rhinitis. Conclusion: Allergen immunotherapy with the 300 IR mite tablet is an effective treatment that relieves allergic symptoms, reduces the need for symptomatic medication, and improves the quality of life in both adults and adolescents with house dust mite-associated allergic rhinitis. At the same time, treatment with the 300 IR mite tablet is well tolerated. Mild to moderate reactions at the application site subside after a few days. © 2023, The Author(s).

引用

页码：10 / 17

页数：7

共 45 条

[1]

Batard T., Baron-Bodo V., Martelet A., Le Mignon M., Lemoine P., Jain K., Et al., Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy, Allergy, 71, pp. 220-229, (2016)

[2]

Calderon M.A., Linneberg A., Kleine-Tebbe J., De Blay F., Hernandez Fernandez de Rojas D., Virchow J.C., Et al., Respiratory allergy caused by house dust mites: What do we really know?, J Allergy Clin Immunol, 136, pp. 38-48, (2015)

[3]

Moingeon P., Progress in the development of specific immunotherapies for house dust mite allergies, Expert Rev Vaccines, 13, pp. 1463-1473, (2014)

[4]

Aggarwal P., Senthilkumaran S., Dust mite allergy, (2022)

[5]

Braido F., Arcadipane F., Marugo F., Hayashi M., Pawankar R., Allergic rhinitis: current options and future perspectives, Curr Opin Allergy Clin Immunol, 14, pp. 168-176, (2014)

[6]

Brehler R., Klimek L., Kopp M.V., Virchow J.C., Specific immunotherapy-indications and mode of action, Dtsch Arztebl Int, 110, pp. 148-158, (2013)

[7]

Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., Casale T.B., Et al., Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision, J Allergy Clin Immunol, 126, pp. 466-476, (2010)

[8]

Meltzer E.O., Bukstein D.A., The economic impact of allergic rhinitis and current guidelines for treatment, Ann Allergy Asthma Immunol, 106, pp. S12-S16, (2011)

[9]

Zuberbier T., Lotvall J., Simoens S., Subramanian S.V., Church M.K., Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review, Allergy, 69, pp. 1275-1279, (2014)

[10]

Linneberg A., Henrik Nielsen N., Frolund L., Madsen F., Dirksen A., Jorgensen T., The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen allergy study, Allergy, 57, pp. 1048-1052, (2002)

← 1 2 3 4 5 →